Asset
MIRICORILANT
CORCEPT THERAPEUTICS INCORPORATED COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06108219 | phase2 | completed | 2023-10-25 | 2026-02-13 | Corcept Therapeutics | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) |
| NCT05117489 | phase1 | completed | 2021-11-23 | 2024-01-29 | Corcept Therapeutics | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) |
| NCT03818256 | phase2 | completed | 2019-12-04 | 2022-06-17 | Corcept Therapeutics | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications |
| NCT03878264 | phase1 | completed | 2018-08-06 | 2019-03-24 | Corcept Therapeutics | Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants |
| NCT07553663 | phase1 | recruiting | 2026-04-30 | 2026-10-30 | Corcept Therapeutics | Evaluating the Pharmacokinetics and Safety of Miricorilant |
FDA applications (0)
This company has no applications containing this asset.